Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Current treatment practice of Guillain-Barré syndrome.

Verboon C, Doets AY, Galassi G, Davidson A, Waheed W, Péréon Y, Shahrizaila N, Kusunoki S, Lehmann HC, Harbo T, Monges S, Van den Bergh P, Willison HJ, Cornblath DR, Jacobs BC; IGOS Consortium.

Neurology. 2019 Jun 7. pii: 10.1212/WNL.0000000000007719. doi: 10.1212/WNL.0000000000007719. [Epub ahead of print]

PMID:
31175208
2.

Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA.

Lancet Neurol. 2019 May 7. pii: S1474-4422(19)30144-9. doi: 10.1016/S1474-4422(19)30144-9. [Epub ahead of print] Review.

PMID:
31076244
3.

Efficient design and analysis of randomized controlled trials in rare neurological diseases: An example in Guillain-Barré syndrome.

van Leeuwen N, Walgaard C, van Doorn PA, Jacobs BC, Steyerberg EW, Lingsma HF.

PLoS One. 2019 Feb 20;14(2):e0211404. doi: 10.1371/journal.pone.0211404. eCollection 2019.

4.

Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis.

Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC.

Neuroepidemiology. 2019;52(3-4):161-172. doi: 10.1159/000494291. Epub 2019 Jan 22.

5.

IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.

Brem MD, Jacobs BC, van Rijs W, Fokkink WJR, Tio-Gillen AP, Walgaard C, van Doorn PA, IJspeert H, van der Burg M, Huizinga R.

Ann Clin Transl Neurol. 2018 Nov 27;6(1):129-143. doi: 10.1002/acn3.687. eCollection 2019 Jan.

6.

International chronic inflammatory demyelinating polyneuropathy outcome study (ICOS): Protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome.

Bunschoten C, Eftimov F, van der Pol WL, Jacobs BC; ICOS Consortium.

J Peripher Nerv Syst. 2019 Mar;24(1):34-38. doi: 10.1111/jns.12296. Epub 2019 Jan 22.

PMID:
30570196
7.

Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity.

Al-Hakem H, Sindrup SH, Andersen H, de la Cour CD, Lassen LL, van den Berg B, Jacobs BC, Harbo T.

J Neurol. 2019 Feb;266(2):440-449. doi: 10.1007/s00415-018-9151-x. Epub 2018 Dec 7.

PMID:
30536111
8.

Mycoplasma Pneumoniae and Antibodies against Galactocerebroside in a 9-Year-Old Boy with Encephalitis.

Smolders J, Jacobs BC, Tio-Gillen AP, Nijhuis F, Verrips A.

Neuropediatrics. 2019 Feb;50(1):54-56. doi: 10.1055/s-0038-1676054. Epub 2018 Nov 26.

PMID:
30477031
9.

Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Meyer Sauteur PM, de Bruijn ACJM, Graça C, Tio-Gillen AP, Estevão SC, Hoogenboezem T, Hendriks RW, Berger C, Jacobs BC, van Rossum AMC, Huizinga R, Unger WWJ.

Infect Immun. 2019 Jan 24;87(2). pii: e00663-18. doi: 10.1128/IAI.00663-18. Print 2019 Feb.

PMID:
30396892
10.

Reply to: Comment on: Zika virus and Guillain-Barré syndrome in Bangladesh.

GeurtsvanKessel CH, Islam Z, Jacobs BC, Endtz HP.

Ann Clin Transl Neurol. 2018 Jul 13;5(9):1140-1141. doi: 10.1002/acn3.619. eCollection 2018 Sep. No abstract available.

11.

Regional variation of Guillain-Barré syndrome.

Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium .

Brain. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232.

12.

[Bell's palsy: different doctor, different care?]

Buizert A, Verboon JC, Wirtz PW, Koopman JP, van Roosmalen RM, Jacobs BC, de Bruijn SFTM.

Ned Tijdschr Geneeskd. 2018 Aug 16;162. pii: D2370. Dutch.

PMID:
30211994
13.

Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.

Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, Cornblath DR, van Doorn PA; Dutch GBS Study Group.

J Peripher Nerv Syst. 2018 Dec;23(4):210-215. doi: 10.1111/jns.12286. Epub 2018 Sep 24.

PMID:
30151941
14.

Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study.

Islam B, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD.

BMJ Open. 2018 Aug 17;8(8):e022862. doi: 10.1136/bmjopen-2018-022862.

15.

Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies.

Taams NE, Notermans NC, Fokkink WR, Tio-Gillen AP, Huizinga R, Schreurs MWJ, Jacobs BC.

J Peripher Nerv Syst. 2018 Dec;23(4):227-234. doi: 10.1111/jns.12285. Epub 2018 Sep 12.

PMID:
30101437
16.

Advances in management of Guillain-Barré syndrome.

Doets AY, Jacobs BC, van Doorn PA.

Curr Opin Neurol. 2018 Oct;31(5):541-550. doi: 10.1097/WCO.0000000000000602. Review.

PMID:
30074496
17.

Reply to: "Association of hepatitis E virus infection and myasthenia gravis: A pilot study".

van Eijk JJJ, Cintas P, Jacobs BC, Kamar N, Dalton HR.

J Hepatol. 2018 Jun;68(6):1321-1322. doi: 10.1016/j.jhep.2018.02.017. No abstract available.

PMID:
29776554
18.

Zika virus and Guillain-Barré syndrome in Bangladesh.

GeurtsvanKessel CH, Islam Z, Islam MB, Kamga S, Papri N, van de Vijver DAMC, Reusken C, Mogling R, Heikema AP, Jahan I, Pradel FK, Pavlicek RL, Mohammad QD, Koopmans MPG, Jacobs BC, Endtz HP.

Ann Clin Transl Neurol. 2018 Apr 6;5(5):606-615. doi: 10.1002/acn3.556. eCollection 2018 May.

19.

Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation.

van den Berg B, Storm EF, Garssen MJP, Blomkwist-Markens PH, Jacobs BC.

J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):949-954. doi: 10.1136/jnnp-2018-317968. Epub 2018 Apr 7.

PMID:
29627773
20.

Zika virus infection in the returning traveller: what every neurologist should know.

Leonhard SE, Lant S, Jacobs BC, Wilder-Smith A, Ferreira MLB, Solomon T, Willison HJ.

Pract Neurol. 2018 Aug;18(4):271-277. doi: 10.1136/practneurol-2017-001789. Epub 2018 Apr 4. Review.

21.

Guillain-Barré syndrome following varicella-zoster virus infection.

Islam B, Islam Z, GeurtsvanKessel CH, Jahan I, Endtz HP, Mohammad QD, Jacobs BC.

Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):511-518. doi: 10.1007/s10096-018-3199-5. Epub 2018 Feb 6.

PMID:
29411189
22.

Intrathecal antibody responses to GalC in Guillain-Barré syndrome triggered by Mycoplasma pneumoniae.

Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, Drenthen J, Unger WWJ, Jacobs E, van Rossum AMC, Jacobs BC.

J Neuroimmunol. 2018 Jan 15;314:13-16. doi: 10.1016/j.jneuroim.2017.11.011. Epub 2017 Nov 16.

PMID:
29301655
23.

Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection.

Leonhard SE, Munts AG, van der Eijk AA, Jacobs BC.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1118-1119. doi: 10.1136/jnnp-2017-317346. Epub 2017 Nov 24. No abstract available.

PMID:
29175895
24.

Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).

Kuitwaard K, Fokkink WR, Brusse E, Vrancken AFJE, Eftimov F, Notermans NC, van der Kooi AJ, Merkies ISJ, Jacobs BC, van Doorn PA.

J Peripher Nerv Syst. 2018 Mar;23(1):5-10. doi: 10.1111/jns.12244. Epub 2017 Nov 21.

PMID:
29119642
25.

Antibody responses to GalC in severe and complicated childhood Guillain-Barré syndrome.

Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, de Wit MY, Unger WWJ, Berger C, van Rossum AMC, Jacobs BC.

J Peripher Nerv Syst. 2018 Mar;23(1):67-69. doi: 10.1111/jns.12243. No abstract available.

26.

Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.

Kuitwaard K, Fokkink WR, Brusse E, Vrancken AFJE, Eftimov F, Notermans NC, van der Kooi AJ, Merkies ISJ, Jacobs BC, van Doorn PA.

J Peripher Nerv Syst. 2017 Dec;22(4):425-432. doi: 10.1111/jns.12242. Epub 2017 Nov 21. Review.

PMID:
29092099
27.

Prediction of disease progression in Miller Fisher and overlap syndromes.

Verboon C, van Berghem H, van Doorn PA, Ruts L, Jacobs BC.

J Peripher Nerv Syst. 2017 Dec;22(4):446-450. doi: 10.1111/jns.12238. Epub 2017 Nov 15.

PMID:
29065229
28.

Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study.

Islam MB, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD.

Pilot Feasibility Stud. 2017 Sep 29;3:40. doi: 10.1186/s40814-017-0185-0. eCollection 2017.

29.

Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy.

van Eijk JJJ, Dalton HR, Ripellino P, Madden RG, Jones C, Fritz M, Gobbi C, Melli G, Pasi E, Herrod J, Lissmann RF, Ashraf HH, Abdelrahim M, Masri OABAL, Fraga M, Benninger D, Kuntzer T, Aubert V, Sahli R, Moradpour D, Blasco-Perrin H, Attarian S, Gérolami R, Colson P, Giordani MT, Hartl J, Pischke S, Lin NX, Mclean BN, Bendall RP, Panning M, Peron JM, Kamar N, Izopet J, Jacobs BC, van Alfen N, van Engelen BGM.

Neurology. 2017 Aug 29;89(9):909-917. doi: 10.1212/WNL.0000000000004297. Epub 2017 Aug 2.

PMID:
28768846
30.

Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study.

Dalton HR, van Eijk JJJ, Cintas P, Madden RG, Jones C, Webb GW, Norton B, Pique J, Lutgens S, Devooght-Johnson N, Woolson K, Baker J, Saunders M, Househam L, Griffiths J, Abravanel F, Izopet J, Kamar N, van Alfen N, van Engelen BGM, Hunter JG, van der Eijk AA, Bendall RP, Mclean BN, Jacobs BC.

J Hepatol. 2017 Nov;67(5):925-932. doi: 10.1016/j.jhep.2017.07.010. Epub 2017 Jul 20.

PMID:
28734938
31.

Could Albumin be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-Barré Syndrome?-Reply.

Fokkink WR, Jacobs BC.

JAMA Neurol. 2017 Jul 1;74(7):872. doi: 10.1001/jamaneurol.2017.0566. No abstract available.

PMID:
28505236
32.

Validated age-specific reference values for CSF total protein levels in children.

Kahlmann V, Roodbol J, van Leeuwen N, Ramakers CRB, van Pelt D, Neuteboom RF, Catsman-Berrevoets CE, de Wit MCY, Jacobs BC.

Eur J Paediatr Neurol. 2017 Jul;21(4):654-660. doi: 10.1016/j.ejpn.2017.03.006. Epub 2017 Apr 8.

PMID:
28461111
33.

High mortality from Guillain-Barré syndrome in Bangladesh.

Ishaque T, Islam MB, Ara G, Endtz HP, Mohammad QD, Jacobs BC, Islam Z.

J Peripher Nerv Syst. 2017 Jun;22(2):121-126. doi: 10.1111/jns.12215.

PMID:
28447405
34.

Motor nerve excitability after childhood Guillain-Barré syndrome.

Drenthen J, Roodbol J, Maathuis EM, Catsman-Berrevoets CE, Blok JH, de Wit MY, Jacobs BC.

J Peripher Nerv Syst. 2017 Jun;22(2):100-105. doi: 10.1111/jns.12213.

PMID:
28432749
35.

International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.

Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA, Willison HJ; IGOS Consortium.

J Peripher Nerv Syst. 2017 Jun;22(2):68-76. doi: 10.1111/jns.12209.

PMID:
28406555
36.

Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies.

Fokkink W, Koch B, Ramakers C, van Doorn PA, van Gelder T, Jacobs BC.

Clin Pharmacol Ther. 2017 Oct;102(4):709-716. doi: 10.1002/cpt.693. Epub 2017 Jun 5.

PMID:
28378901
37.

Diagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteria.

Roodbol J, de Wit MY, van den Berg B, Kahlmann V, Drenthen J, Catsman-Berrevoets CE, Jacobs BC.

J Neurol. 2017 May;264(5):856-861. doi: 10.1007/s00415-017-8429-8. Epub 2017 Mar 1.

38.

Hepatitis E Virus Infects Neurons and Brains.

Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, van der Kroeg M, Zhao M, Yin Y, Wang W, Cao W, Wang Y, Kushner SA, Marie Peron J, Alric L, de Man RA, Jacobs BC, van Eijk JJ, Aronica EMA, Sprengers D, Metselaar HJ, de Zeeuw CI, Dalton HR, Kamar N, Peppelenbosch MP, Pan Q.

J Infect Dis. 2017 Apr 15;215(8):1197-1206. doi: 10.1093/infdis/jix079.

PMID:
28199701
39.

Guillain-Barré syndrome: surveillance and cost of treatment strategies - Authors' reply.

Willison HJ, Jacobs BC, van Doorn PA.

Lancet. 2017 Jan 21;389(10066):253-254. doi: 10.1016/S0140-6736(17)30055-7. Epub 2017 Jan 20. No abstract available.

PMID:
28118915
40.

Zika Virus Infection and Guillain-Barré Syndrome in Three Patients from Suriname.

Langerak T, Yang H, Baptista M, Doornekamp L, Kerkman T, Codrington J, Roosblad J, Vreden SG, De Bruin E, Mögling R, Jacobs BC, Pas SD, GeurtsvanKessel CH, Reusken CB, Koopmans MP, Van Gorp EC, Alberga H.

Front Neurol. 2016 Dec 22;7:233. doi: 10.3389/fneur.2016.00233. eCollection 2016.

41.

Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.

Fokkink WR, Walgaard C, Kuitwaard K, Tio-Gillen AP, van Doorn PA, Jacobs BC.

JAMA Neurol. 2017 Feb 1;74(2):189-196. doi: 10.1001/jamaneurol.2016.4480.

PMID:
28027337
42.

Hepatitis E virus: Infection beyond the liver?

Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA.

J Hepatol. 2017 May;66(5):1082-1095. doi: 10.1016/j.jhep.2016.11.016. Epub 2016 Nov 29. Review.

PMID:
27913223
43.

Treatment dilemmas in Guillain-Barré syndrome.

Verboon C, van Doorn PA, Jacobs BC.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):346-352. doi: 10.1136/jnnp-2016-314862. Epub 2016 Nov 11. Review.

PMID:
27837102
44.

Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes.

Halstead SK, Kalna G, Islam MB, Jahan I, Mohammad QD, Jacobs BC, Endtz HP, Islam Z, Willison HJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6):e284. eCollection 2016 Dec.

45.

Guillain-Barré syndrome in Bangladesh: validation of Brighton criteria.

Islam MB, Islam Z, Farzana KS, Sarker SK, Endtz HP, Mohammad QD, Jacobs BC.

J Peripher Nerv Syst. 2016 Dec;21(4):345-351. doi: 10.1111/jns.12189.

PMID:
27616152
46.

Tracheostomy or Not: Prediction of Prolonged Mechanical Ventilation in Guillain-Barré Syndrome.

Walgaard C, Lingsma HF, van Doorn PA, van der Jagt M, Steyerberg EW, Jacobs BC.

Neurocrit Care. 2017 Feb;26(1):6-13. doi: 10.1007/s12028-016-0311-5.

47.

Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: A case-control study.

Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, Roodbol J, Hoogenboezem T, Jacobs E, van Rijn M, van der Eijk AA, Vink C, de Wit MC, van Rossum AM, Jacobs BC.

Ann Neurol. 2016 Oct;80(4):566-80. doi: 10.1002/ana.24755. Epub 2016 Aug 26.

PMID:
27490360
48.

Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS.

Fokkink WJ, Haarman AE, Tio-Gillen AP, van Rijs W, Huizinga R, van Doorn PA, Jacobs BC.

Ann Clin Transl Neurol. 2016 May 17;3(7):547-51. doi: 10.1002/acn3.307. eCollection 2016 Jul. Erratum in: Ann Clin Transl Neurol. 2017 Jan 09;4(1):71.

49.

Proximal nerve lesions in early Guillain-Barré syndrome: implications for pathogenesis and disease classification.

Berciano J, Sedano MJ, Pelayo-Negro AL, García A, Orizaola P, Gallardo E, Lafarga M, Berciano MT, Jacobs BC.

J Neurol. 2017 Feb;264(2):221-236. doi: 10.1007/s00415-016-8204-2. Epub 2016 Jun 17. Review.

PMID:
27314967
50.

Neuronal endocytosis of anti-ganglioside antibodies: implications for Guillain-Barré syndrome.

van Doorn PA, Jacobs BC.

Brain. 2016 Jun;139(Pt 6):1622-5. doi: 10.1093/brain/aww078. No abstract available.

PMID:
27234059

Supplemental Content

Loading ...
Support Center